Fund shareholders of Coherus Oncology Inc
ISIN US19249H1032 · United States · LEI 5493007IL8W5MV932D26
- Fund shareholders
- 113
- Of which ETFs
- 19 94 other funds
- Value held
- 30.5M $
- Share of capital
- 11.6 % of 154.5M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 2,347 | 4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Destinations Small-Mid Cap Equity Fund Brinker Capital Destinations Trust | 1,851 | 3.1K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ULTRA SMALL CAP PROFUND ProFunds | 1,171 | 2.1K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 554 | 983.4 $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 541 | 914.3 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 346 | 584.7 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 262 | 442.8 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 233 | 393.8 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 189 | 335.5 $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 149 | 251.8 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 109 | 182 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 33 | 55.1 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 28 | 47.3 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Simplify Propel Opportunities ETF Simplify Exchange Traded Funds | 0.62 % | as of Mar 31, 2026 ↗ |
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 0.58 % | as of Feb 28, 2026 ↗ |
| Ultra-Small Company Fund Bridgeway Funds, Inc. | 0.58 % | as of Mar 31, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 0.23 % | as of Mar 31, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 0.21 % | as of Mar 31, 2026 ↗ |
| AQR Small Cap Multi-Style Fund AQR Funds | 0.11 % | as of Mar 31, 2026 ↗ |
| BlackRock Advantage Small Cap Growth Fund BlackRock Funds | 0.04 % | as of Mar 31, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.04 % | as of Mar 31, 2026 ↗ |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 0.03 % | as of Feb 27, 2026 ↗ |
| AQR Small Cap Momentum Style Fund AQR Funds | 0.03 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 113 | +9 | 17,955,985 | -5.1 % |
| 2026Q1 | 104 | -2 | 18,914,801 | -10.1 % |
| 2025Q4 | 106 | +6 | 21,044,991 | -4.2 % |
| 2025Q3 | 100 | -9 | 21,965,692 | -6.7 % |
| 2025Q2 | 109 | -2 | 23,535,079 | -1.9 % |
| 2025Q1 | 111 | -10 | 23,998,349 | -1.7 % |
| 2024Q4 | 121 | -7 | 24,409,065 | +5.0 % |
| 2024Q3 | 128 | +8 | 23,255,738 | +6.2 % |
| 2024Q2 | 120 | -14 | 21,899,936 | -0.3 % |
| 2024Q1 | 134 | -30 | 21,965,784 | -35.9 % |
| 2023Q4 | 164 | 34,274,279 |
Institutional managers
152 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 10,365,074 | 17.5M $ | as of Mar 31, 2026 |
| SAMSARA BIOCAPITAL, LLC | 3,428,571 | 5.8M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,121,578 | 5.3M $ | as of Mar 31, 2026 |
| Kohlberg Kravis Roberts & Co. L.P. | 3,036,076 | 5.1M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 2,325,859 | 3.9M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 2,302,001 | 3.9M $ | as of Mar 31, 2026 |
| Alyeska Investment Group, L.P. | 2,250,000 | 3.8M $ | as of Mar 31, 2026 |
| CM Management, LLC | 2,100,000 | 3.5M $ | as of Mar 31, 2026 |
| C WorldWide Group Holding A/S | 1,928,464 | 3.3K $ | as of Mar 31, 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1,886,748 | 3.2M $ | as of Mar 31, 2026 |
| Hudson Bay Capital Management LP | 1,704,980 | 2.9M $ | as of Mar 31, 2026 |
| PANAGORA ASSET MANAGEMENT INC | 1,459,310 | 2.5M $ | as of Mar 31, 2026 |
| Propel Bio Management, LLC | 1,420,550 | 2.4M $ | as of Mar 31, 2026 |
| AQR CAPITAL MANAGEMENT LLC | 1,206,046 | 2M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,155,901 | 2M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 913,800 | 1.5M $ | as of Mar 31, 2026 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 899,999 | 1.5M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 696,158 | 1.2M $ | as of Mar 31, 2026 |
| UBS Group AG | 547,209 | 924.8K $ | as of Mar 31, 2026 |
| SEI INVESTMENTS CO | 453,763 | 766.9K $ | as of Mar 31, 2026 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 441,000 | 745.3K $ | as of Mar 31, 2026 |
| Invesco Ltd. | 335,309 | 566.7K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 331,700 | 560.6K $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 324,133 | 547.8K $ | as of Mar 31, 2026 |
| STRS OHIO | 324,000 | 547.6K $ | as of Mar 31, 2026 |
Declared shareholders of Coherus Oncology Inc
There are 3 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 8.30 % | 12,750,800 | as of Mar 31, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 4.90 % | 7,337,261 | as of Mar 31, 2026 · SCHEDULE 13G |
| Thomas A. Satterfield, Jr. | 4.60 % | 6,930,000 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Coherus Oncology Inc". https://titelia.com/en/stocks/coherus-oncology-inc-US19249H1032